

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address. COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO. FI		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/987,485 11/14/2001		11/14/2001	Michael A. Barry	15987/282434	15987/282434 7070	
909	7590	03/26/2003				
PILLSBU	RY WINT	THROP, LLP	EXAMINER			
P.O. BOX 10500 MCLEAN, VA 22102				LI, BA	LI, BAO Q	
				ART UNIT	PAPER NUMBER	
				1648		
				DATE MAILED: 03/26/2003	DATE MAILED: 03/26/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>							
	Application No.	Applicant(s)					
*	09/987,485	BARRY ET AL.					
Office Action Summary	Examiner	Art Unit					
	Bao Qun Li	1648					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication(s) filed on 23 A	<u>pril 2002</u> .						
2a) ☐ This action is FINAL . 2b) ☐ Thi	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-36</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 1-36 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1.☐ Certified copies of the priority documents have been received.							
Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)					

 $I_{\geq 0}$

Application/Control Number: 09/987,485

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-4, 7-9, 15-17, drawn to a fusion protein of a non-envelope virus, classified in class 424, subclass 192.1.

Upon election of Group I, Applicant is additionally required to elect a single biotinylation-competent protein or peptide to be examined on the merits. This requirement is not to be construed as a requirement for an election of species, since each of the fusion protein or peptide recited in alternative form is not a member of a single genus of invention, which has different structure and different patenable weight that constitutes an independent and patentably distinct invention. They are (1). Pyruvate carboxylase, (2). Propionyl-ConA carboxylase, (3). Acetyl Con A carboxylase (4). Methylcrotonyl ConA carboxylase, and (5) a PSTCD peptide

- II. Claims 5-6, 10-14, 18-21, 34-36, drawn to a vector and a method for making a fusion protein by using a biotinylation-competent protein or peptide to join directly with polypeptide of interest, classified in class 435, subclass 69.1.
- III. Claims 22-23 and 27-28, drawn to a fusion protein of fusion protein of an envelope virus consisting of a biotin receptor peptide of SEQ ID NO: 3, classified in class 435, subclass 188.1.
- IV. Claim24-26, 29-33, drawn to a vector and a method for producing a retrovirus envelope fusion protein by using a biotin receptor peptide, classified in class 435, subclass 320.1.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of groups I and III are drawn to structurally and functionally different fusion protein or peptide, e.g. the fusion protein of Group I comprising a protein or peptide of a non-envelope

Application/Control Number: 09/987,485

Art Unit: 1648

virus, whereas the fusion protein or peptide of Group II comprising a protein or peptide of an envelope virus.

- 3. Inventions of groups II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of groups II and IV are different methods by using different approaches for making two kinds of fusion protein, e.g. the method of group II is using a biotinylation-competent protein or peptide to join the polypeptide of interest, whereas the method of Group IV is use of a biotin-receptor peptide.
- 4. Inventions Group I and II or Group II and IV are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed can be made by another and materially different process such as a fusion peptide made by a polyhistadine tag or a hemagglutin (HA) tag, rather than using a biotinylation-competent protein or peptide.
- 5. Because these inventions are distinct for the reasons given above. For example, the search required for Group I is not required for Group III. Therefore, the restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/987,485

Art Unit: 1648

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 703-305-1695. The examiner can normally be reached on 7:00 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Bao Qun Li

March 24, 2003

JAMES HOUSEL 3/24/03
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600